Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
TRENDS
Drug Makers’ Payments to Medical Institutions Dip for Second Year: Jiho Tally
Pharmaceutical companies in Japan saw their payments to medical institutions dwindle 6% in FY2014, falling for the second straight year, with payouts for academic research support including controversial “scholarship donations” shrinking over 20%, according to a Jiho tally. The tally…
To read the full story
Related Article
- 5 Years after Transparency Guidelines Rollout, R&D Costs Halve while Dining Outlays About to Disappear
October 1, 2018
- 74 Drug Makers Paid 483.1 Billion Yen to Healthcare Providers in FY2013: Jiho Tally
March 9, 2015
- Chugai Led in Research Grants Payment in FY2013; Grants Fell Among Major Drug Makers
November 5, 2014
TRENDS
- Top 10 Most-Read PHARMA JAPAN Articles in 2023
December 28, 2023
- Top 10 PHARMA JAPAN Articles in 2022
December 28, 2022
- 15 APIs with 10 Billion Yen-Plus Peak Sales Outlooks Listed in 2021: Jiho Tally
December 28, 2021
- Top 10 PHARMA JAPAN Articles in 2021
December 28, 2021
- Top 10 PHARMA JAPAN Articles in 2020
December 28, 2020
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…